The ASCO Post Podcast

Latest Episodes:

First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma Sep 05, 2019

Show notes

This week, we’ll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we’ll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we’ll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.

Coverage of stories discussed this week on ascopost.com:

Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCC

Key Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer Types

Exposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students

Pooled Survival Analysis of Patients With NSCLC Treated With Nivolumab Aug 30, 2019

Show notes

This week, we review a pooled analysis of long-term survival rates in patients with previously treated non–small cell lung cancer treated with nivolumab. We then turn to the recently reported USPSTF recommendation on risk assessment, genetic counseling, and genetic testing for BRCA1 or BRCA2 mutations. Lastly, we discuss the recent FDA approval of entrectinib for NTRK-fusion cancers and ROS1-positive NSCLC.

Coverage of stories discussed this week on ascopost.com:

Pooled Analysis of 4-Year Survival With Nivolumab Therapy in Patients With Previously Treated Advanced NSCLC

USPSTF Recommendation on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA -Related Cancer

FDA Approves Entrectinib for NTRK -Fusion Cancers, ROS1 -Positive NSCLC

USPSTF Recommendation Against Pancreatic Cancer Screening in Asymptomatic Adults Aug 22, 2019

Show notes

This week, we review the U.S. Preventive Services Task Force (USPSTF) recommendation against screening for pancreatic cancer in adults with no symptoms. We also talk about the discovery of a germline mutation that has been newly associated with pancreatic cancer. Lastly, we discuss a U.S. Food and Drug Administration review which concluded a common Parkinson’s disease drug does not contribute to the development of prostate cancer.

Coverage of stories discussed this week on ascopost.com:

USPSTF Recommendation on Screening for Pancreatic Cancer in Asymptomatic Adults

Germline RABL3 Mutation May Increase Risk of Pancreatic Cancer Development

FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone

Ibrutinib and Rituximab vs Standard Chemoimmunotherapy in CLL Aug 16, 2019

Show notes

This week, we review a report on the combination of ibrutinib and rituximab vs standard chemoimmunotherapy in some patients with chronic lymphocytic leukemia (CLL); a study on cancer statistics in adults aged 85 and older; and a decision from the Centers for Medicare and Medicaid Services (CMS) on coverage of chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.

Coverage of stories discussed this week on ascopost.com:

Ibrutinib/Rituximab vs Standard Chemoimmunotherapy in Previously Untreated CLL

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

Erdafitinib for FGFR-Altered Advanced Urothelial Carcinoma Aug 09, 2019

Show notes

This week, we review a phase II trial of erdafitinib in urothelial carcinoma with an FGFR alteration.

We also talk about a report from the World Health Organization on tobacco use worldwide.

Then, we discuss two recent FDA approvals in prostate cancer and a rare joint tumor.

Coverage of stories discussed this week on ascopost.com:

Erdafitinib in FGFR -Altered Advanced Urothelial Carcinoma

WHO Releases Report on the Global Tobacco Epidemic

FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor

Overall Survival in MONALEESA-7 Aug 01, 2019

Show notes

This week, we discuss an interim analysis of the MONALEESA-7 trial of the addition of ribociclib to endocrine therapy in pre- or perimenopausal women with advanced hormone receptor–positive, HER2-negative breast cancer.

We also talk about a study that examined the relationship between the duration of chemotherapy and body mass index and the development of lymphedema in some patients with breast cancer.

Lastly, we present three recent approvals and regulatory communications from the FDA.

Coverage of stories discussed this week on ascopost.com:

Overall Survival With the Addition of Ribociclib to Endocrine Therapy in Advanced HR-Positive, HER2-Negative Breast Cancer

Neoadjuvant Chemotherapy Duration and Obesity May Be Associated With Increased Risk of Lymphedema in Some Women With Breast Cancer

FDA Approves Rituximab Biosimilar for Non-Hodgkin Lymphoma, CLL, and Autoimmune Conditions

FDA Requests Manufacturer Recall of Some Textured Breast Implants

FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer

Rates of Early-Onset Colorectal Cancer Jul 26, 2019

Show notes

This week, we discuss a study that found a disconnect between rates of colonoscopy and recent increases in colorectal cancer incidence in younger adults.

In addition, Dr. Kimmie Ng, of Dana-Farber Cancer Institute, offers her insights on the rising rates of colorectal cancer in young adults.

Then, we turn to a report on the relationship between androgen-deprivation therapy and rates of Alzheimer disease and dementia in elderly patients with prostate cancer.

Coverage of stories discussed this week on ascopost.com:

Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends

Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients

Long-Term Results From the National Lung Screening Trial Jul 19, 2019

Show notes

This week, we discuss long-term results from an extended analysis of the National Lung Screening Trial, and Dr. James Mulshine of Rush University offers his thoughts on these findings.

We also review a report on radioactive iodine treatment for hyperthyroidism and long-term risk of death from solid cancers.

Coverage of stories discussed this week on ascopost.com:

Extended Follow-up From the National Lung Screening Trial Reported

Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?

ESMO World GI: Findings From the BEACON CRC Trial and More Jul 11, 2019

Show notes

We discuss two studies on colorectal cancer that were presented at the ESMO World Congress on Gastrointestinal Cancer. We also talk about a recently published study on the prevalence of pain among cancer survivors in the U.S.

Coverage of stories discussed this week on ascopost.com:

BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer

REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer

Chronic Pain in U.S. Cancer Survivors

ICML 2019: Role of Liquid Biopsy in Lymphoma Jul 03, 2019

Show notes

In this episode, The ASCO Post's Editor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of patients with lymphoma. He also discusses two studies from the plenary session looking at the impact of adding lenalidomide to R-CHOP in the management of diffuse large B-cell lymphoma.
Later in the podcast, we discuss findings from the PHARE trial on adjuvant trastuzumab dosing in HER2-positive breast cancer and we report two recent approvals by the FDA.

Coverage of stories discussed this week on ascopost.com:

Final Analysis of the PHARE Trial: 6 Months vs 12 Months of Adjuvant Trastuzumab in HER2-Positive Breast Cancer

FDA Approves Daratumumab in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed, Transplant-Ineligible Patients With Multiple Myeloma

FDA Approves Bevacizumab Biosimilar for Five Cancer Types

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected